Literature DB >> 15237654

[Treatment of achalasia].

Enrico P Cosentini1, Etienne Wenzl, Raimund Jakesz.   

Abstract

Achalasia is a condition of unknown etiology. It represents a motor disorder of the esophagus characterized by absent or incomplete relaxation of the lower esophageal sphincter upon swallowing and by non-propulsive swallow-induced contraction waves or amotility of the esophageal body. Dysphagia and regurgitation of ingesta are the most frequent symptoms. Medical treatment, i.e. by calcium-channel blockers and nitric oxide donors, may be tried in patients with mild dysphagia or in elderly patients but rarely yields adequate symptom relief. Mechanical dilatation of the achalasic sphincter may be performed as an initial treatment option. Intrasphincteric injections of botulinum toxin seemed to be a promising alternative, but it has become obvious that, in most cases, repeated applications of the toxin are required to maintain patients symptom-free. Myotomy of the achalasic sphincter with or without fundoplication to prevent gastroesophageal reflux, is employed mainly in patients in whom dilatations have failed, but since the introduction of minimally invasive surgery, myotomy has become the primary treatment at many centers. This article aims to provide an overview of the development of the conservative and surgical treatment of achalasia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237654     DOI: 10.1007/BF03040899

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  84 in total

1.  Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia.

Authors:  M G Patti; C V Feo; M Arcerito; M De Pinto; A Tamburini; U Diener; W Gantert; L W Way
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

2.  Gastroesophageal reflux in achalasia. When is reflux really reflux?

Authors:  P F Crookes; S Corkill; T R DeMeester
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

3.  Effects of sildenafil on esophageal motility of patients with idiopathic achalasia.

Authors:  M Bortolotti; C Mari; C Lopilato; G Porrazzo; M Miglioli
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

4.  Inflammatory aetiology of primary oesophageal achalasia: an immunohistochemical and ultrastructural study of Auerbach's plexus.

Authors:  L Raymond; B Lach; F M Shamji
Journal:  Histopathology       Date:  1999-11       Impact factor: 5.087

Review 5.  The place of esophageal manometry in the diagnosis of dysphagia.

Authors:  H Feussner; W Kauer; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

Review 6.  Achalasia.

Authors:  J C Reynolds; H P Parkman
Journal:  Gastroenterol Clin North Am       Date:  1989-06       Impact factor: 3.806

Review 7.  Current therapies for achalasia: comparison and efficacy.

Authors:  M F Vaezi; J E Richter
Journal:  J Clin Gastroenterol       Date:  1998-07       Impact factor: 3.062

8.  Achalasia and chest pain: effect of laparoscopic Heller myotomy.

Authors:  Silvana Perretta; Piero M Fisichella; Carlos Galvani; Maria V Gorodner; Lawrence W Way; Marco G Patti
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

9.  Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.

Authors:  M Gelfond; P Rozen; T Gilat
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

10.  Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh.

Authors:  P J Howard; L Maher; A Pryde; E W Cameron; R C Heading
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

View more
  1 in total

1.  Videoendoscopy and histopathology of the esophagogastric junction in patients with gastroesophageal reflux disease.

Authors:  Claudia Ringhofer; Johannes Lenglinger; Margit Eisler; Fritz Wrba; Roland Sedivy; Johannes Zacherl; Enrico P Cosentini; Gerhard Prager; Elena Devyatko; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.